Introduction
Zika virus (ZIKV) continuous spread has affected more than 80 countries 1 and no licenced vaccine is currently available 2 . The Asian-lineage is the causative agent of major outbreaks across the globe and most of the current ZIKV vaccine candidates aim to provide homologous efficacy in ZIKV pre-clinical challenge models 2, 3 . In contrast, the African-lineage of ZIKV is mainly restricted to sylvatic transmission but not much is known about the ability of this virus to emerge from a sylvatic to human transmission. Efficacy of ZIKV vaccine in mice or macaques relies on the quantification of viraemia by RT-PCR 4 . However, questions remain as to whether current ZIKV vaccine candidates offer lineage-transcending protection and viral clearance in key organs, such as the brain and reproductive tract. Here, we show the cross-protective capabilities of our previously reported simian adenoviral-vectored zika vaccines 5 (ChAdOx1 ZIKV) against a heterologous African-ZIKV challenge model, in which A129 mice display a high susceptibility to ZIKV infection 6 . Furthermore, we have assessed the ability of our vaccines to prevent infection in tissues such as the brain and ovaries, as both tissues are relevant for ZIKV pathogenesis [7] [8] [9] . Finally, we describe a novel ChAdOx1 ZIKV vaccine design carrying a consensus antigen of the African-ZIKV lineage and tested its efficacy in a homologous challenge model.
Main
The recent Zika outbreaks have emerged from relative obscurity almost 70 years after ZIKV was discovered 13 . The commonality from those outbreaks is that the ZIKV AS was the causal agent. Currently, this lineage still continues to spread to many countries in which the Aedes mosquito vector is prevalent, which is an efficient vector of ZIKV. Importantly, ZIKV is a flavivirus known to infect key organs such as the brain 14 and reproductive tract 15 , causing Gillian Barré syndrome and microcephaly in new-borns. ZIKV has been shown to be sexually-transmitted and to persist long after ZIKV infection in the testis and other fluids such as semen and urine 16 . Therefore, an ideal Zika vaccine must afford complete sterile protection regardless of the ZIKVlineage and overcome viral persistence in tissues related to the pathogenic features of ZIKV, all in a single and unadjuvanted vaccination approach. While considerable progress has been made at testing several vaccine candidates in Non-Human Primate (NHP) challenge studies [17] [18] [19] [20] , in which viraemia is the main correlate of ZIKV infection; little is known of whether the complete elimination of ZIKV from blood can correlate with sterile protection in these immune privileged organs.
Previously, we have reported the generation of four ChAdOx1 ZIKV vaccine candidates based on an Asianlineage sequence, and their protective efficacy in a homologous ZIKV-lineage challenge model 5 . Although all vaccines demonstrated protective efficacy, we found that a vaccine carrying the prM and the envelope gene without its 3' transmembrane domain (prME ∆ TM) induced long-term anti-envelope antibodies and cleared viraemia with 100% efficacy after only a single and unadjuvanted vaccination 5 . Here, we tested the efficacy of those vaccines against a heterologous ZIKV challenge in a highly susceptible rodent model 6, 21 . In addition, we generated a novel ChAdOx1 ZIKV vaccine candidate (ChAdOx1 CprME/NS) based on a consensus sequence from the African-lineage ZIKV (Figure 1a ). This carries the full structural gene cassette fused to the non-structural NS2b and NS3 antigens, which are both required to allow the cleavage of Capsid (C) from prM/envelope while exposing the amino terminal region of prM 22 , and tested its efficacy in a homologous ZIKV challenge. 6-8 weeks old, Type-I Interferon receptor knock-out A129 mice were intramuscularly vaccinated (in a blinded experiment) with 10e 8 IU of ChAdOx1 ZIKV vaccines (n=6), and four weeks after vaccination mice were challenged with a subcutaneous injection of the African-lineage ZIKV strain, MP1751 (Figure 1b) . To monitor humoral immune responses elicited by the vaccines, blood samples were taken one day before the ZIKV challenge. After the ZIKV challenge, vaccine efficacy was assessed by measuring the percentage of survival, based on standardised humane time-points such as 20%
weight loss and clinical manifestations of ZIKV infection (clinical score) 6 . Animals that met humane clinical endpoints between 7-9 days after challenge (dac) or at the end of the study (21 dac) were culled and blood, spleen, brain, liver and ovaries were collected for histology studies (microscopic lesions), in situ hybridisation (ISH), and to assess ZIKV loads by qRT-PCR.
To gain a comprehensive assessment of vaccine efficacy, temperature-sensing microchips were implanted into A129 mice to monitor the temperature in all vaccinated and control groups. The temperatures were monitored for 30 days before the ZIKV challenge (dbc), including the vaccination day and onwards, and for 21 days after challenge (dac), or until animals reached humane endpoints ( Figure 2a and Supplementary   Figure 1 ). Upon challenge, mock-vaccinated (ChAdOx1 Unrelated vaccine) and PBS control mice displayed a gradual increase, followed by a rapid decrease, of temperature ( Figure 2a , brown and orange line), which has been described earlier 6 . In contrast, ChAdOx1 ZIKV vaccines were not associated with a gradual increase in temperature ( Figure 2a , black arrowhead). The temperatures at the fever stage were significantly lower when compared to control groups ( Figure 2b ). However, the one-day rapid temperature decrease was observed in the ChAdOx1 Env and ChAdOx1 Env ∆ TM groups, which followed the same trend as the unrelated vaccine and PBS groups ( Figure 2a , grey arrowhead). ChAdOx1 prME, prME ∆ TM and CprME/NS groups did not appear to have this rapid decrease of temperature. After the challenge, all animals were monitored three times a day for clinical signs of disease and a numerical score was assigned for each observation. Clinical signs of disease were observed from 5 to 7 dac in all mice from the unrelated vaccine and CprME/NS groups (i.e. ruffled fur or hunched). Interestingly, no clinical signs of disease were observed in the ChAdOx1 prME. In parallel, the weight of animals was monitored 30 dbc and 21 dac or until animals met the humane endpoint of 20% of weight loss (Figure 2d ). In the control groups, unrelated and PBS, the 20% weight loss occurred first and animals were culled between 6 and 7 dac. ChAdOx1 Env vaccine showed similar weight loss dynamics, although a 2-day delay was observed. The ChAdOx1 Env ∆ TM group lost weight rapidly but after 9 dac the animals recovered. ChAdOx1 prME ∆ TM and CprME/NS presented <10% weight loss and by the end of the study all the animals recovered normal weight, indicating full recovery. All mice from the ChAdOx1 prME group remained relatively unchanged in the critical days in which control groups lost weight (Figure 2d ).
Based on the humane endpoints (20% weight loss and clinical scores) the percentage of survival was calculated ( Figure 3a) . Upon challenge with 100 pfu ZIKV, all of the negative control animals met humane clinical endpoints within 7-8 dac. ChAdOx1 Env failed to provide protective efficacy, whilst the deletion of TM from Env in ChAdOx1 Env ∆ TM, rescued several animals providing 66% protection. Interestingly, three of the vaccine candidates provided 100% protection: the Asian-lineage based vaccines ChAdOx1 prME and ChAdOx1 prME ∆ TM, as well as the African-lineage based vaccine ChAdOx1 CprME/NS. We sought to analyse the levels of anti-ZIKV envelope antibodies at 1 dbc by using ELISA plates coated ZIKV AS envelope 23 ( Figure 3b ). Sera from control groups were negative and Log10 reciprocal titers showed that all ChAdOx1
ZIKV vaccines elicited anti-envelope responses. A ZIKV-specific reciprocal of >1 was detected in all ChAdOx1 ZIKV AS vaccinated animals, with the ChAdOx1 prME ∆ TM group having the highest titer followed by ChAdOx1 prME. Interestingly, ZIKV envelope antibody titers from the ChAdOx1 CprME/NS sera group were the lowest by ELISA, although all mice from this group were protected after the ZIKV challenge.
In our previous study 5 we used a non-lethal challenge model in BALB/C mice and we measured vaccine efficacy in vivo by means of partial or complete reduction of viraemia by qRT-PCR. Here, we analysed the viral loads in blood from both protected and unprotected A129 mice by qRT-PCR ( Figure 3c ). As expected, high levels of viremia were detected in the ChAdOx1 unrelated and the PBS groups. However, each
ChadOx1 ZIKV vaccinated group prevented viraemia, regardless of the survival outcome ( Figure 3a) ; i.e. the ChAdOx1 Env group in which all animals met humane endpoints, or the ChAdOx1 prME in which all animals were protected after the ZIKV challenge. These results point out key observations: 1) the presence or absence of viraemia is not a definitive correlate of protective efficacy, and 2) ZIKV, if not found in blood, might be present in different tissues.
To gain a better understanding of protective efficacy versus viral load, we analysed the presence of ZIKV by qRT-PCR in the brain from both the animals that reached humane endpoints and the surviving mice ( Figure   4a ). For the control groups, unrelated and PBS as well as the ChAdOx1 Env group, ZIKV RNA was detected in the brain at the humane endpoint 7-8 dac. For the vaccinated group ChAdOx1 Env ∆ TM (60% survival), viral loads were high in the brain for those animals that were culled by d8, whereas detectable levels where found in 2 out of 4 of surviving animals by 21 dac, which suggests that ZIKV is able to persist long after ZIKV exposure in animals immunised with sub-optimal vaccines. On the other hand, no ZIKV persistence was detected in any of the brain samples from the 100% surviving groups vaccinated with ChAdOx1 prME, and prME ∆ TM) as well as meningeal infiltration, whereas minimal to mild changes in the brain were observed with the remaining animals and staining for the viral antigen was negative. We did not detect marked inflammation of the meninges within the protected groups ChAdOx1 prME, prME ∆ TM and CprME/NS. Finally, although the qRT-PCR was negative in the brain samples from groups prME and prME ∆ TM, ZIKV RNA was observed in rare cases through single cell-staining by ISH (Figure 4c ). However, due to deposits of staining reagent, the presence of rare positive cells might reflect a staining artefact. A summary of the severity of microscopic lesions in the brain is summarised in Supplementary Table 1 .
We extended the analysis to the ovaries in which ZIKV levels were detected in the ChAdOx1 unrelated and Levels of ZIKV in the spleen were also investigated by qRT-PCR. ZIKV RNA was detected in control animals by ISH (Figure 4e ). Viral loads were not found in any of the spleens from the ChAdOx1 prME group, whereas 5 out of 6 mice from the ChAdOx1 prME ∆ TM group displayed several log fold decreases in viral loads when compared to the groups that received PBS or a ChAdOx1 unrelated vaccine. Importantly, high ZIKV levels were detected in the non-optimal ChAdOx1 Env, the sub-optimal ChAdOx1 Env ∆ TM, and in the highly-protective ChAdOx1 CprME/NS.
Histopathological changes in the spleen are primarily considered to be reactive changes to ZIKV infection and provide supportive evidence of infection severity. We found alterations in the spleen in control animals such as poorly defined areas of white pulp (Figure 4f , left panel). This profound alteration was not present in the ChAdOx1 prME, ChAdOx1 prME ∆ TM (Figure 4f , right panel) and the ChAdOx1 CprME/NS. Similarly, we found the presence of polymorphonuclear leucocytes (PMN) in the control groups, but normal levels were recorded in all mice vaccinated with the ChAdOx1 prME, prME ∆ TM and CprME/NS (Supplementary Table   1 ). Extra-medullary haematopoiesis (EMH) was observed within all the groups, with marked to moderate effects within the control and ChAdOx1 Env groups, and mild to minimal effects on the rest of ChAdOx1 ZIKV-vaccinated groups (Supplementary Table 1 ).
Finally, ZIKV RNA was not detected in the liver by either qRT-PCR in any of the groups involved in this study 24 . However, lesions of mild to moderate severity were detected by histology in the control and PBS vaccinated groups, as well as in the ChAdOx1 Env-vaccinated group, while the rest of the ChAdOx1 ZIKVvaccinated groups presented characteristics within normal limits, with minimal effects in the foci of EMH with apoptosis (Supplementary Table 1 ).
Taken together, ChAdOx1 ZIKV vaccines demonstrate a range of protective effects upon ZIKV challenge.
Adenoviral vectors carrying the full envelope gene of ZIKV but prM showed no protective attributes.
Vaccine efficacy is improved leading to partial protection (66%) when the transmembrane domain is deleted (Env ∆ TM), and the addition of the prM with envelope increases efficacy to 100 % in the prME, prME ∆ TM and CprME/NS vaccine candidates. Of all the vaccine candidates, the ChAdOx1 prME showed the greatest protective correlates, as the animals from this group did not exhibit any signs of disease after ZIKV challenge and viral RNA was not detectable by PCR in any of the tissues collected at necropsy. In this study, we vaccinated and challenged female A129 mice with ZIKV, it would be very useful to follow up the efficacy of this and other vaccine candidates in gender-randomised groups of mice, to assess the presence of ZIKV in reproductive tissue such as testis, ovaries, and the reproductive tract. More importantly, testing those vaccines in a ZIKV-transmission model would be essential to completely rule-out ZIKV transmission through the sexual route.
In this work, we found that non-protected vaccinated mice (i.e. ChAdOx1 Env) met humane endpoints by eight dac, and surprisingly, no ZIKV was detected in the blood of these animals by RT-PCR, but high levels were detected in the brain. Furthermore, 66% of the mice vaccinated with ChAdOx1 Env ∆ TM showed full recovery after challenge, and yet we were still able to detect viral within the brain 21 dac, suggesting that ZIKV persistence is an important feature worthy of further clinical and preclinical vaccine developments.
Equally important is the fact that ZIKV challenge models in NHP rely mainly on the presence or absence of ZIKV in the blood. Interestingly, ZIKV persistence in NHP has been documented in the cerebrospinal fluid and lymph nodes 25 . It is important to acknowledge that although viraemia is an important correlate of vaccine efficacy, this parameter may not reflect the capacity of other vaccine candidates to generate protection in other organs such as neural and reproductive tissue.
Finally, we have developed a Zika vaccine based on the African ZIKV-lineage, which contains the whole structural cassette and fused to the non-structural proteins NS2b/NS3. This vaccine conferred 100%
protective efficacy as none of the animals met humane end-points. However, the average of ELISA endpoint titers to ZIKV envelope was low in this group in comparison to those from mice protected or unprotected (ChAdOx1 prME ∆ TM and ChAdOx1 Env, respectively). Furthermore, ZIKV RNA was detected in the brain of 1 out of 6 animals at 21 dac and we cannot rule out whether this is viral RNA traces nor it has infective capabilities. The question remains whether these observations are due to a suboptimal elicitation of immune responses, or a suboptimal vaccination with ChAdOx1 CprME/NS. Finally, ChAdOx1CprME/NS contains the antigen NS2b and importantly NS3, which has been shown to induce T cell immunity in ZIKV, DENV and other flavivirus 26 . Future studies comparing CprME/NS versus the sole insertion of the ZIKV NS3 will provide further insights into the mode of action of this vaccine. Harnessing ZIKV vaccines that are able to elicit both antibodies against structural antigens and specific T cell responses against non-structural proteins or vice versa, create new and interesting possibilities in the search for suitable ZIKV vaccine candidates. Table 1 Histology changes observed in A129 mice challenged with ZIKV. Colours depict severity of lesions, being green minimal or WNM, yellow being mild and red being moderate to severe.
Material and Methods

Animals
Forty-two female A129 mice (5-6 weeks old) were purchased from a home office approved breeder and supplier (B&K Universal Ltd, part of Marshall BioResources). The mice were implanted with a temperature and identity chip (idENTICHIP with Bio Thermal) upon arrival (n=6 mice per group). During three-day rest, baseline observations of behaviour, temperature and weight were recorded. The experimental design accounted for the 3R reduction (Replacement, Reduction, Refinement). No randomisation was used in this work.
Transgene design
Design and production of the ZIKV Asian-based vaccines ChAdOx1 Env, ChAdOx1 Env ∆ TM, ChAdOx1 prME and ChAdOx1 prME ∆ TM have been previously reported 5 . For the African Lineage vaccine design, DNA coding the Capsid (C), prM and Envelope (E) coding sequences (794 a.a.), joined to the NS2b (127 a.a.) and NS3 (616 a.a.) was codon optimised. Transgene design included the required enzymatic restriction sites to allow the in-frame cloning of the transgene between the CMV promoter and the Poly(A) sequence region contained in our shuttle and expression vector (pMono). Synthetic gene cassette was produced by
GeneArt and was named CprME/NS.
Vaccine production of ChAdOx1 CprME/NS
The CprME/NS transgene was digested with KpnI and NotI to allow in-frame ligation between the CMV promoter and the Poly(A) regions contained into an expression plasmid (pMono). pMono CprME/NS plasmid was expanded in E. coli. The entry plasmid containing attL regions sequences was recombined with those attR regions contained in the destination vector ChAdOx1 using an in vitro Gateway reaction (LR Clonase II system, Invitrogen). Successfully recombined ChAdOx1 CprME/NS plasmid was verified by DNA sequencing using flanking primers (promoter forward primer and Poly-(A) Reverse primer). Standard cell biology and virology techniques were performed to generate the non-replicative adenoviral vectors 27 .
Immunisation of mice
Mice were vaccinated with a single dose of chimpanzee adenoviral vectored vaccine (ChAdOx1) encoding the ZIKV antigens at a dose of 1x10 8 infectious units (IU). All vaccines were administered intramuscularly (i.m.) in the right hind limb and diluted in endotoxin-free PBS. ChAdOx1 expressing an unrelated malarial antigen (cTRAP) were used as control vaccines.
Ethics statement
All animals and procedures were used in accordance with the terms of the UK Home Office Animals Act Project License. Animal experiments performed at PHE were approved These studies were approved by the ethical review process of Public Health England, Porton Down, UK, and by the Home Office, UK via an Establishment Licence (PEL PCD 70/1707) and project licence (30/3147). A set of humane endpoints based on clinical manifestation of disease were defined in the protocol of the project licence and are described below.
Challenge virus
All mice were challenged with 100 pfu of African strain ZIKV (MP1751) via the subcutaneous (s.c.) route to mimic mosquito bite; 40ul into the right leg and 40l into left leg toward the ankle.
Sample collection
When animals met humane clinical endpoints or at the end of the study (21 days post-challenge) they were culled by an approved Schedule 1 method. The following samples were collected at necropsy:
Blood: 100 µl in an RNA protect tube and frozen in an ultra-low freezer with the reminder into serum separation tubes.
Spleen: half to be placed in Precellys tubes and frozen in an ultra-low freezer, the remainder in a histology pot Brain: 2/3rds LHS+ (or most intact) to be placed in a histology pot, the remainder to be placed in Precellys tubes and frozen in an ultra-low freezer.
Liver: small section to be placed in Precellys tubes and frozen in an ultra-low freezer. A section (no more than 3mm thick) to be placed into a histology pot
Ovaries: LHS to be placed in a histology pot, the RHS to be placed in Precellys tubes and frozen in an ultralow freezer.
Clinical Measurements
During the course of the study, weights and temperatures were collected at least once daily and clinical scores assessed at least twice a day. During critical periods of the study the monitoring intensity was increased to allow humane clinical endpoints to be more rapidly captured and reduce any potential suffering of animals with severe disease. Clinical scores were assigned a numerical value for analysis purposes: 0, normal; 2, ruffled fur; 3, lethargy, pinched, hunched, wasp-waisted; 5, laboured breathing, rapid breathing, inactive, neurological; and 10, immobile. To prevent unnecessary suffering to animals, humane clinical endpoints were used where animals would be culled upon reaching any of the following criteria:
Immobility defined as a lack of movement even after a stimulus such as handling;
Neurological signs including repetitive or unusual movement;
Weight loss of 20% or more compared to maximum recorded weight from days 1-3 pre-challenge or prevaccination; or continual vocalisation.
Pre-challenge bleed
On day 27 post-vaccination, a blood sample from each mouse was taken (no more than 100 μl) into SST tubes for serum isolation.
Whole IgG Enzyme-linked immunosorbent assay
96-well plates coated with ZIKV envelope protein and blocked with Pierce Blocking Protein-free reagent.
Serial dilutions (3-fold) of sera from vaccinated mice were added. Diluted sera were incubated at RT for 1 h, and after four times washing buffer incubations, 100 Reactions were run and analysed on the QuantStudio platform (Applied Biosystems, UK).
Quantification of viral load in samples was performed using a dilution series of quantified RNA oligonucleotide (Integrated DNA Technologies). The oligonucleotide comprised the 77 bases of ZIKV RNA targeted by the assay, based on GenBank accession AY632535.2 and was synthesised to a scale of 250 nmol with HPLC purification.
Histology
Samples of brain, ovary, liver and spleen were fixed in 10% neutral buffered saline and processed routinely to paraffin wax. Sections were cut at 3-5 μm, stained with haematoxylin and eosin and examined microscopically. Lesions referable to infection were scored subjectively using the following scale: within normal limits, minimal, moderate and marked. The pathologist was blinded to the groups in order to prevent bias.
RNA in situ hybridisation (ISH)
RNA ISH was performed with an RNAscope 2.5 (Advanced Cell Diagnostics) according to the manufacturer's instructions. In brief, formalin-fixed paraffin-embedded tissue sections were deparaffinised by incubation at 60 min at 60°C. Hydrogen peroxide treatment for 10 min at room temperature quenched endogenous peroxidases. Slides were then boiled for 15 min in RNAscope Target Retrieval Reagents and incubated for 30 min in RNAscope Protease Plus before hybridisation. For probes, V-ZIKA-pp-O1-sense (Advanced Cell Diagnostics, catalogue no. 463791) was used due to having 99% specificity with the MP1751 challenge strain of ZIKV. Tissues were counterstained with Gill's haematoxylin and visualised with standard bright-field microscopy. Each slide was scanned systematically so all areas of the tissue were assessed.
Statistics
Graphing and statistical analysis were performed using GraphPad Prism version 7.00 for Mac, GraphPad
Software, La Jolla California USA, www.graphpad.com. To assess differences between groups, a two-way ANOVA followed by Multiple comparison was performed. All graphs were plotted with bars and errors, representing the mean and the s.d. Dots represent each individual between groups. Assumptions of data are:
normal distribution, homogeneity, independent, and groups must have same sample size.
